Valuation: Cipla Limited

Market Cap 1,140B 12.13B 10.88B 9.94B 9.07B 17.1B 17.63B 120B 47.78B 608B 45.52B 44.54B 1,920B P/E 2027 *
29x
P/E 2028 * 22.7x
Enterprise Value 1,043B 11.1B 9.95B 9.1B 8.3B 15.64B 16.14B 110B 43.72B 557B 41.65B 40.76B 1,757B EV / Sales 2027 *
3.41x
EV / Sales 2028 * 2.92x
Free-Float
68.87%
Yield 2027 *
0.89%
Yield 2028 * 1.01%
1 week+4.23%
Current month+2.07%
1 month+6.47%
3 months-2.63%
6 months+5.71%
Current year-11.90%
1 week 14.6
Extreme 14.6
14.8
1 month 13.5
Extreme 13.5
14.8
Current year 12.8
Extreme 12.8
17
1 year 12.8
Extreme 12.8
17.3
3 years 12.8
Extreme 12.8
20
5 years 10.4
Extreme 10.4
20
10 years 4.94
Extreme 4.94
20
Manager TitleAgeSince
Chief Executive Officer - 31/03/2026
Director of Finance/CFO - 23/07/2026
President - 17/05/2026
Director TitleAgeSince
Chairman 90 21/07/1972
Director/Board Member 72 24/07/2014
Director/Board Member 71 29/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.23% - - 12B
-0.13%-3.68%+45.65%+129.41% 1,216B
+0.46%+0.00%+46.13%+80.10% 656B
+0.48%-1.89%+32.09%+104.90% 509B
-0.36%-3.25%+47.17%+64.58% 384B
-0.23%-1.90%+71.00%+40.58% 362B
-0.78%-0.52%+30.57%+57.98% 311B
-0.80%-0.21%+8.54%+35.56% 293B
+0.03%-1.18%+45.92%+68.79% 249B
+0.18%-1.77%+35.87%+106.64% 208B
Average -0.19%+0.60%+40.33%+76.50% 465.31B
Weighted average by Cap. -0.12%+0.03%+42.22%+88.47%

Financials

2027 *2028 *
Net sales 306B 3.25B 2.92B 2.67B 2.43B 4.58B 4.73B 32.12B 12.81B 163B 12.2B 11.94B 515B 346B 3.68B 3.3B 3.02B 2.75B 5.19B 5.35B 36.36B 14.5B 185B 13.81B 13.52B 583B
Net income 39.28B 418M 375M 343M 313M 589M 608M 4.13B 1.65B 20.96B 1.57B 1.53B 66.17B 50.19B 534M 479M 438M 400M 753M 776M 5.28B 2.1B 26.78B 2B 1.96B 84.55B
Net Debt -96.77B -1.03B -923M -844M -770M -1.45B -1.5B -10.17B -4.06B -51.64B -3.86B -3.78B -163B -130B -1.38B -1.24B -1.13B -1.03B -1.95B -2.01B -13.64B -5.44B -69.26B -5.18B -5.07B -219B
Projected Income Statement - Annual - Cipla Limited
Logo Cipla Limited
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Employees
31,369
Date Price Change
05/11/26 US$14.80 0.00%
04/11/26 US$14.80 +0.68%
03/11/26 US$14.70 +0.68%
02/11/26 US$14.60 +0.69%
30/10/26 US$14.50 +2.11%
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Cipla Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,411.00INR
Average target price
1,507.31INR
Spread / Average Target
+6.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipla Limited